Page 1

NANOBIOTIX EXPANDING LIFE Nanobiotix provides second quarter operational and financial update July 20 , 2021 • Presented updated results from priority pathways in head and neck cancer and immunotherapy for potential first- in - class radioenhancer NBTXR3 at 2021 Annual Meeting of The American Society for Clinical Oncology • Established new strategic partnership with LianBio to develop and commercialize NBTXR3 across tumor types and therapeutic combinations in China and other Asian markets • Strengthened global leadership team through the appointment of Gary Phillips as Chairman of the Nanobiotix Supervisory Board and Bart Van Rhijn as Chief Financial Officer • Reported € 102.3 million in cash , cash equivalents , and short - term investments as of June 30 , 2021 Paris , France ; Cambridge , Massachusetts ( USA ) ; July 20 , 2021 – NANOBIOTIX ( Euronext : NANO — NASDAQ : NBTX - the " Company " ) , a late - clinical stage biotechnology company pioneering physics - based approaches to expand treatment possibilities for patients with cancer , today announced operational progress and cash position ( unaudited ) for the second quarter of 2021 . Second Quarter Financial Updates Nanobiotix reported total revenue for the six - month period ended June 30 , 2021 of € 9.7k . Revenue for the first half of 2021 was primarily driven by cross charges related to the Company's previous collaboration with PharmaEngine , Inc. , during the first quarter 2021. Nanobiotix did not generate any revenue during the second quarter of 2021. Revenue for the second quarter and first half of 2020 amounted to € 13.4k and € 36.9k respectively . Nanobiotix reported cash , cash equivalents , and short - term investments totaling € 102.3 million as of June 30 , 2021 , compared to € 107.1 million as of March 31 , 2021. This amount includes the € 16.5 million ( $ 20.0 million ) upfront payment associated with the LianBio collaboration announced in May 2021. As previously announced , PharmaEngine was eligible for and received a € 2.1 million ( $ 2.5 million ) payment following the announcement of Nanobiotix's collaboration with LianBio and has received € 3.4 million ( $ 4.0 million ) in conjunction with the completion of various administrative steps in connection with the winding - up of the collaboration . PharmaEngine will be eligible to receive an additional $ 1.0 million in administrative fees and a final payment of $ 5 million upon a second regulatory approval of an NBTXR3 - containing product . Nanobiotix plans to report half - year financial results for the six - months ended June 30 , 2021 , including condensed consolidated financial statements for the period , on September 8 , 2021 . Second Quarter Operational Highlights • Presented Updated Results from Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First - In - Class Radioenhancer NBTXR3 at 2021 Annual Meeting of The American Society for Clinical Oncology ( ASCO ) : • Local Control as a Single - Agent for Patients with Head and Neck Cancer : Updated data from Study 102 , a phase I study evaluating NBTXR3 as a single agent activated by radiotherapy in locally advanced head and neck squamous cell carcinoma ( LA- HNSCC ) presented at ASCO further support NBTXR3 administration as feasible , and well - tolerated with a favorable safety profile in highly vulnerable elderly LA - HNSCC patients with high unmet medical needs and significant burden of disease . At a median follow up of 8.1 months , evaluable patients ( n = 40 ) demonstrated a high primary tumor ORR of 82.5 % and a 62.5 % CRR . These results are consistent with those observed in the dose escalation part of the study and suggest durability of efficacy . Nanobiotix plans to launch a pivotal phase III global registration study evaluating NBTXR3 as a single - agent activated by radiotherapy for patients with LA - HNSCC in the second half of 2021 . • Priming Immune Response and Immunotherapy Combination Across Oncology : Updated data from Study 1100 , a phase I basket study evaluating NBTXR3 activated by radiotherapy ( RT ) in combination with nivolumab or pembrolizumab in locoregional recurrent or recurrent metastatic HNSCC , lung metastasis from any primary tumor and / or liver metastasis from any primary tumor showed tumor regression in 76.9 % of evaluable patients ( n = 13 ) regardless of prior anti - PD - 1 exposure . Data from this ongoing study show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti - PD - 1 non - responders into responders . • Formed Strategic Partnership with LianBio to Develop and Commercialize NBTXR3 Across Tumor Types and Therapeutic Combinations in China and other Asian markets : • LianBio's cross - border development and commercialization expertise includes strong capabilities in oncology : LianBio will participate in the Nanobiotix global phase III HNSCC registrational study by enrolling 100 patients in China . In addition to the phase III head and neck cancer study , LianBio has committed to enrolling patients in four additional registrational studies conducted by Nanobiotix across indications and therapeutic combinations . Under